KRAS and pancreatic adenocarcinoma: From a genetic point of view, none of the included m6A genes had a mutation frequency of more than 1% in TCGA and ICGC database; compared with the mutation frequency of control genes KRAS and TP53. Thus, we had enough reason to believe that mutations of m6A regulatory genes were not a common event in PAAD patients (Figure 2).